January 16, 2025 10:08 AM ESTUpdated 11:09 AM
News Briefing

Boehringer's schiz­o­phre­nia as­set fails Phase 3; GSK buys organoid biotech

ENDPOINTS

Plus, news about Ko­di­ak Sci­ences, Out­look Ther­a­peu­tics and Avac­ta:

Boehringer In­gel­heim re­ports Phase 3 schiz­o­phre­nia fail: The drug, icleper­tin,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ex­clu­sive: CRISPR de­liv­ery start­up, based on UC Berke­ley and UCSF sci­ence, shuts down

Start­up that mines ‘junk DNA’ se­cures R&D deal with Mer­ck

Pfiz­er’s man­u­fac­tur­ing arm at risk from Trump tar­iffs in Eu­rope, Bourla says

Su­per­nus’ stock sinks af­ter place­bo ef­fect de­rails mid-stage de­pres­sion study

For­mer FDA chief calls job cuts ‘hap­haz­ard, poor­ly thought-out’

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times